Trividia Health Announces Jonathan Chapman as President and Chief Executive Officer
15.9.2021 11:00:00 EEST | Business Wire | Press release
Trividia Health, Inc., a leading supplier of blood glucose monitoring systems, announced today that Jonathan Chapman has been appointed as President and Chief Executive Officer. Mr. Chapman succeeds Scott Verner in the role.
Mr. Chapman brings over 20 years of leadership experience in the medical device industry, with an accomplished track record of driving growth, developing strategic alliances, launching products globally, and optimizing business operations.
In addition to his newly assumed responsibilities at Trividia Health, Mr. Chapman will continue to serve as President and Chief Executive Officer of PTS Diagnostics, Inc.
“Jonathan has proven himself as the right leader for PTS Diagnostics and is the right leader for Trividia,” said Shaobo Li, Chairman of the Board at both Trividia Health and PTS Diagnostics. “Jonathan’s extensive background in successfully running medical device companies and his business development skills will help both organizations to reach the next level of growth and evolution. Jonathan is a results-oriented, dynamic, and innovative business leader. I am confident he has the right track record, commitment, vision and judgment to lead Trividia and PTS Diagnostics.”
“I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes,” said Jonathan Chapman, President and CEO of Trividia Health and PTS Diagnostics. “I look forward to working with my colleagues at Trividia. With their support, focus on customers and continuing dedication, we will build on Trividia’s legacy of bringing leading innovation to patients across the globe.”
Mr. Chapman received a Bachelor of Arts from Sheffield University UK, LLM Commercial and Corporate Law from University of London (SOAS) and LLM Health Law from Hamline Law School, St. Paul, MN. Trividia is confident that his international experience will be immensely valuable when leading the organization across global markets.
About Trividia Health
Trividia Health, Inc., is a global health and wellness company with over 30 years experience in the industry. Based in Fort Lauderdale, Florida, Trividia is a leading developer, manufacturer and marketer of advanced performance products for people and pets with diabetes. With products sold under the TRUE brand, store brand labels and Healthy Tracks for Pets, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005226/en/
Contact information
Neal Bhattacharya, Sr. Director, Product Marketing
(800) 342-7226, ext. 3150 – nbhattacharya@trividiahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 23:08:00 EET | Press release
Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl
Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 23:05:00 EET | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven successful deployments at customers across the retail and manufacturing industries. The suite leverages NVIDIA’s software components including Metropolis, Omniverse, and Nemotron. All solutions offer flexible deployment at the edge, in on-premises datacenters, or in the cloud, enabling customers to achieve an optimal balance between inference cost, latency, privacy, and other operational requirements. The suite covers the following use cases, tailored to the needs of retail and manufacturing
Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 23:01:00 EET | Press release
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind down. We grew our core Rimini Support™ subscription billings and launched our next generation Agentic AI ERP solutions that can be easily and quickly deployed over the top of existing ERP Software without the cost or risk of unnecessary ERP Software upgrades, migrations or replatforming,” said
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 19:25:00 EET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO ® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 19:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), show vedolizumab’s promising efficacy and safety profile in a patient population where therapy options remain limited.With KEPLER, Takeda is continuing to generate deeper scientific insights and identify additional patient populations who may benefit from vedolizumab, a cornerstone therapy for adults with ulcerative colitis. Vedolizumab is marketed under the trade name ENTYVIO®*. “Ulcerative colitis is a life-altering diagnosis for young patients and their families, often leaving t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom